NorthWest Biotherapeutics Inc (NWBO)

[Slave1]

No, nothing in the 10-Q suggests that approval is contingent on the new Grade C suite being completed. The filing makes clear that MHRA review of the MAA is already underway, based on the existing, fully licensed and fully validated manufacturing infrastructure that Advent has been using for years. The company explicitly states that the current Sawston facility has already completed Phases 1A and 1B, has licensed Grade B and Grade C cleanroom capacity, and is actively conducting manufacturing operations, including SOW-8 cleanroom validation runs, comparability work, APS, PPQ, and other GMP activities inside the existing cleanrooms  . The new Grade C suite described in the recent PR is a capacity expansion, not a prerequisite for approval. It is being built to support Eden automation and commercial-scale throughput, but the approval review is proceeding on the basis of the current validated system. Regulatory agencies do not halt or delay approval because a sponsor is expanding future capacity; they evaluate whether the sponsor can safely and consistently manufacture the product right now, and the 10-Q makes clear that Advent’s existing infrastructure already meets that requirement.